How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?

Opinion
Video

A nurse practitioner and two hematologic oncologists outline diagnosis and staging practices for patients with multiple myeloma.

This is a video synopsis/summary of a Between the Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.

Rodriguez discusses how multiple myeloma (MM) is diagnosed and staged. Diagnosis involves blood work such as complete blood count to check hemoglobin, comprehensive metabolic panel to assess renal function and calcium level, serum protein electrophoresis to identify abnormal immunoglobulins (M protein), immunofixation electrophoresis, and serum free light chains to evaluate M protein fragments. These data indicate whether abnormal proteins from myeloma cells are present and their type, quantity, and integrity. Additional blood tests such as lactate dehydrogenase (LDH), β2 microglobulin, and albumin facilitate staging. Urine studies check for free light chains or Bence-Jones proteins. Imaging such as PET-CT identifies lytic bone lesions and extramedullary plasmacytomas. Alternative imaging includes low-dose contrast-enhanced CT or whole-body MRI. Bone marrow biopsy results from the iliac crest or from plasmacytomas characterize disease, and staging uses cytogenetics, albumin, β2 microglobulin, and LDH.

Video synopsis is AI generated and reviewed by CancerNetwork® editorial staff.

Recent Videos
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
Related Content